Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL: GM-CSF and Exercise in PAD
NCT01408901Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Sep 2011
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in Peripheral Arterial Disease (PAD), sponsored by Northwestern University. Started Sep 2011; status: completed.
02
Drugs
sargramostim
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT01408901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01408901.